Explore the latest advances in RSV vaccine research, and what these developments mean for prevention and public health.
Nirsevimab significantly reduced respiratory syncytial virus (RSV)–associated hospitalizations in infants during the 2024-2025 season, consistent with previous findings. The study used a large dataset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results